Alzheimer’s isn’t just one problem—it’s a tangled mix of biology, aging, and overall health. That’s why drugs targeting a single factor have fallen short, even as new treatments show modest benefits.

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. More and more American companies are planning to invest in Trump Accounts. The accounts, set to launch ...